The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2 by unknown
THE RECONSTITUTION OF CELL-MEDIATED IMMUNITY
IN THE CUTANEOUS LESIONS OF LEPROMATOUS
LEPROSY BY RECOMBINANT INTERLEUKIN 2
BY GILLA KAPLAN,' ROLF KIESSLING,$ SABAWORK TEKLEMARIAM,$
GERALD HANCOCK,' GIULIA SHEFTEL,' C. K. JOB,11 PAUL CONVERSE,1
TOM H . M. OTTENHOFF,T MARIJKE BECX-BLEUMINK,§
MARTIN DIETZ,§ AND ZANVIL A. COHN'
From 'The Rockefeller University, New York, New York 10021; the lArmauer Hansen Research
Institute (AHRI), Addis Ababa, Ethiopia; the §All Africa Leprosy Rehabilitation and Training
Centre (ALERT), Addis Ababa, Ethiopia; and the Il Gillis W . Long Hansen's Disease Center,
Carville, Louisiana 70721
Thebasic defect in lepromatous leprosy is the selective unresponsiveness ofTcells
to the antigens of Mycobacterium leprae (1) . This defect may be partial or complete
(2) and does not appear to change with prolonged chemotherapy (3). A lack ofT
cell-derived lymphokines such as IFN-y and IL-2 could account for the inability
of macrophages and other cells to eliminateM . leprae .
Attempts to circumvent T cell unresponsiveness have already been initiated in
both in vitro systems (2, 4-6) and in the confines of the cutaneous lesions . Initial
observations have been reported on the efficacy of crossreacting antigens such as
purified protein derivative of tuberculin (PPD)' and the lymphokine rIFN- .y (7-10) .
In the case ofPPD, intradermal administration has led to a long-lived emigratory
mononuclear leukocyte response, the local destruction of parasitized macrophages,
and a striking reduction in the number ofM . leprae within 21 d . These responses
and the accompanying modification of cellular subsets are evidence ofa vigorous
cell-mediated immune reaction in the environment ofalepromatous lesion . Similar
observations have been made after IFN-y administration (manuscript in preparation).
We have now extended these observations to the use ofhuman rIL-2. This lym-
phokine serves as an autocrine T cell growth factor, and induces the formation of
lymphokines with otherfunctions (11, 12) . We report resultson the useof smalldoses
of IL-2, in the skin of lepromatous patients, and the reconstitution of cutaneous
cellular immunity.
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Materials and Methods
Patient Population .
￿
35 patients, 18-60 yr old, 23 with lepromatous leprosy (LL) and 12
with borderline lepromatousleprosy (BL) (13), were selected for the intradermal administra-
This work was supported by Cetus Corporation and by National Institutes of Health grant AI-22616 .
AHRI is affiliated withALERT Hospital, Addis Ababa, and is supportedby the NorwegianandSwedish
Save The Children Fundsandby the Norwegian(NORAD)and Swedish(SIDA) international develop-
ment agencies .
1 Abbreviations used in this paper: BI, bacterial index; BL, borderline lepromatous leprosy ; DTH,
delayed-type hypersensitivity ; LL,lepromatous leprosy ; PPD, purified protein derivative of tuberculin.
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tion of rIL-2 (Cetus Corp., Emeryville, CA). Patients were referred to the study from the
out-patient clinic at the All Africa Leprosy Rehabilitation and Training Centre (ALERT,
Addis Ababa). Some of the patients were hospitalized or newly diagnosed patients. Leprosy
patients in reaction or on steroid treatment were excluded from the study. Patients were in-
formed of the nature of the study and written consent was obtained from all participants.
Patients had been treated from 1 wk to 5 yr, and had received multidrug therapy with
Rifampin (600 mg/d), Dapsone (100 mg/d) and about halfreceived Clofazimine (50-100 mg/d
and/or 300 mg/mo) in addition.
Patients were admitted to the ALERT Addis Ababa Leprosy Hospital and routine labora-
tory tests were performed on blood, urine, and stools. A general clinical and neurological
exam was conducted. All chemotherapy was continued during the trial. Slit smears for bac-
terial index (BI) evaluation were performed a day or two before IL-2 injection. The BI of
patients tested ranged from 3 to 5+ .
IL-2 Administration.
￿
Human rIL-2 (3 x 106 U/mg protein) was transported and stored
at 4°C until used. The lyophilized IL-2 was reconstituted in pyrogen-free sterile water and
diluted in 5 % dextrose to a concentration of 100 or 250 lAg/ml and used within 2 h ofreconsti-
tution. Eight patients received a single dose of 10 lag rIL-2, six received a single dose of 25 Ftg
rIL-2, four received two 10-Ag doses at 48-h intervals, and 17 received three 10-kg doses at
48-h intervals. Patients receiving one to two doses of IL-2 were injected in apparently normal
skin on the lower back, while patients injected with three doses were tested in macular or
nodular lepromatous lesions. Local erythema and induration of the injected site were evalu-
ated daily. These studies were carried out at the Armauer Hansen Research Institute (AHRI),
Addis Ababa. The site of IL-2 injection and a matched control site were biopsied (4-mm
punch) 1-21 d after IL-2 administration, cut into three parts, and processed for evaluation
as described below.
Histopathology and Enumeration of Bacilli.
￿
A part of each biopsy was fixed in 10% neutral
buffered formalin overnight, embedded in paraffin, sectioned, and stained for histological
examination. Some of the biopsies were stained by the Triff stain for immediate evaluation
ofhistologic changes. The rest ofthe tissue was transported back to the U. S., sectioned, and
stained with hematoxylin and eosin for histological diagnosis and with acid-fast staining for
enumeration of M. leprae. A logarithmic index of bacilli in the biopsies (14, 15) was used to
express bacterial numbers in control and IL-2-injected sites. Of the 35 patients tested, only
22 had a high enough BI to be used for bacterial reduction analysis.
Immunohistology.
￿
Biopsy specimens were fixed in paraformaldehyde (3%), lysine (0.075
M), and sodium-m-periodate (0.01 M) in PBS (PLP) for 3-4 h at 4°C as described by McLean
and Nakane (16). This fixative preserves structural details without inhibiting the binding of
mAbs to their antigens. The biopsies were washed in PBS containing sucrose (10%) and
digitonin (5 x 10-5 M) and then serially suspended in graded solutions of sucrose (15-25%).
The tissue was stored in PBS with sucrose/glycerol (25% and 5%, respectively) for transport
back to the U. S. and until frozen.
Biopsies were embedded in OCT compound and frozen at -20°C ; 6-8-Jm sections were
cut on a cryostat and applied to gelatin-coated multi-well slides (Carlson Scientific Inc., Peo-
tone, IL). The sections were dried overnight at 37°C, rehydrated in PBS, and incubated with
mouse mAbs followed by biotinylated horse anti-mouse Ig and then avidin-biotin peroxidase
complexes (Vector Laboratories, Inc., Burlington, CA). The reaction product was developed
with 0.8 mg/ml 3-amino-9-ethylcarbazole and 0.015% H202. Sections were counterstained
with hematoxylin.
Monoclonal andPblyclonalAntibodies.
￿
Mouse mAbs were used for the identification of specific
cell types. Leu-1, Leu-2a, and Leu-3a (17, 18) (CD5, CD4, and CD8 antiT cells) and Leu-
M5 (CDllc anti-monocyte/macrophage) (19) were obtained from Becton Dickinson & Co.
(Mountain View, CA). OKT6 (20) (CDl anti-Langerhans' cells) was obtained from Ortho
Diagnostic Systems, Inc. (Westwood, MA) . Antibody 93F10 (anti-MHC class II antigen)
was produced in this laboratory (21). Rabbit anti-,y IP-10 antibodies were produced in this
laboratory (22).
Determination ofEpidermal Thickness.
￿
Epidermal thickness was evaluated by direct exami-
nation of hematoxylin-stained sections using a computer-based image digitizing system(Southern MicroInstruments, Inc., Atlanta, GA). Thedistance from the epidermal-dermal
junction to the outer surfaceof theepidermiswas measured at equalintervalsalongthelength
of the sections. At least 25 measurements were made per section. Results were expressed
as the ratio of mean thickness of the IL-2-injected site vs. the control site for each patient.
EM
￿
A part of each biopsy was processed for transmission EM studies. Biopsies were
washed in saline at 4°C, cut into 1-2-mm pieces, and fixed in 2.5% glutaraldehyde in 0.1
M cacodylate buffer with 0.1 M sucrose, pH 7.4, for 16 h at 40C. The tissues were cut to
1 mm or smaller and postfixed in 2% Os04 for 6 h at 40C. The tissue was then stained en
block for 2 h with 0.25% uranyl acetate, dehydrated in increments with ethanol, and em-
bedded in epon blocks. Semi-thinsections were stainedwith methylene blue-azur-basic fuchsin
and examined for areas containing infiltrating cells. Sections were stained with uranyl ace-
tate andlead citrate, andexamined with a transmission EM (model JEM 100CX;Jeol USA,
Peabody, MA). At least 200 cells from each patient were examined and photographed on
Kodak electron image film.
Results
Local IL-2 Responsiveness ofLepmmatous Patients.
￿
The local reaction to the intradermal
injection of a single dose of 10 or 25 ug of rIL-2 into apparently normal skin of
lepromatous leprosy patients is shown in Fig. 1 A. All theinjected patients responded
FIGURE 1.
￿
Localinduration in response to rIL-
2 administration. (A) The area of induration in
response to a single intradermal injection of 10
lag(A)or 25 lag(O)ofrIL-2. Themean response
for all the patients tested is shownby theclosed
symbols.Induration washigh at 24 handreduced
at 48 h. (B) The area of induration in response
to two or three intradermal injections of 10 lag
rIL-2 administered at 48-h intervals. Results are
meansofinduration. Thebars denote 1 SD and
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to the injection of IL-2 . The extent of induration (radius of indurated area) was
proportional to the dose oflymphokine administered both at 24 and 48h after injec-
tion . Induration peaked at 24 h and decreased at 48 h, to a level that persisted for
4-7 d (not shown) . This response is comparable with a strong delayed-type hyper-
sensitivity (DTH) response, but DTH usually persists for at least 96 h without any
decrease (10) .
Thelocal response to multiple doses of 10 FAg IL-2 given at 48-h intervals is shown
in Fig . 1 B. As in the previous group of patients, the initial induration after the
first, second, and third injection (24, 72, and 120 h) was reduced 24 h later at 48,
96, and 144 h, respectively . The area of induration induced by the first injection
was not enhanced by subsequent injections . On the contrary, the third injectiondid
not lead to induration above the basal level observed at 48 and 96 h . This suggested
an unresponsiveness to IL-2 at 96 h . The basal induration observed at 96 and 144 h
persisted for up to 2 wk . By 3 wk afterlymphokine administration, 8-10mm of in-
duration was still observed in about half of the patients biopsied at that time (not
shown) . Other than an erythematous skirt about the 24-h site, no otherlocal or sys-
temic reactions were noted.
TheLocal Cellular Response to rIL-2Administration.
￿
Histological and immunohisto-
logical sections of IL-2-injected and control sites biopsied 2-21 d after lymphokine
administration were used for the evaluation of the local cellular response to lym-
FIGURE 2 .
￿
The extent of dermal infiltration in response to rIL-2. Immunohistologic staining
of cryostat sections with anti-Ia . Biopsies were taken from a patient (Table I, patient 4) at time
0 (a) and at 48 h after a single 10 -F+g rIL-2 injection (c)andfrom another patient (Table I, patient
17) at time 0 (b) and 21 d after three 10 -FAg injections of rIL-2 (d) . Note the extensive staining
of cells in the dermis, the thickening of the epidermis, and the expression of Ia on the surface
of the keratinocytes after IL-2 administration (x 50) .phokine. The controlsitestaken from nonlesional "normal" skin contained an inflam-
matory infiltrate of lepromatous leprosywith perivascular aggregates of mononuclear
leukocytes involving from <5-30% of the dermis (Fig. 2, a and b and Table I). Con-
trol biopsies taken from macular or nodularlepromatous lesions demonstrated dermal
infiltration of 5-95% (Table I). Theinjection ofrIL-2 into theskin induced an early
extensive recruitment of new mononuclear cells that enhanced the percent of the
dermis involved (Fig. 2, c andd). The enhancement in cellularity was evaluated and
expressed as the ratio of the area of dermis containing inflammatory cells in the
IL-2 vs. the control site. As illustrated in Fig. 3 A, the increase in dermal, cellular
infiltration was well established by 48 h, peaked at 4 d, and then subsided. By 3 wk
the percent of the dermis involved at the IL-2 site had returned to the control level
in the majority of patients.
The steep decline in cellularity after the last injection of IL-2 suggested that the
lymphokine could be changing thenormal turnover and or recirculation of thelym-
KAPLAN ET AL.
TABLE I
Influence of IL-2 on the Bacterial Indices ofLepromatous Leprosy Lesions
897
<6 + , patchy reduction, some areas 6 + , others 5 + or less.
* The diagnosis was the histologic diagnosis of the control and IL-2 injected biopsies according to the Ridley
Jopling scale.
$ The reduction in BI is expressed in BI units (log units) and is the difference between the control and the
IL-2 BI in the adjacent columns. t, <10-fold.
S Granulomata were defined by the presence of epithelioid and multinucleated giant cells.
B Subpolar lepromatous leprosy.
IL-2 injected into "normal skin" between nodular lesions.
** IL-2 injected into nodular lesions. All other patients injected into "normal skin" or macular lesions.
Patient
Dose
IL-2
Time
biopsy
Percent infiltration
Control IL-2
Diagnosis*
Control IL-2
Bacterial
Control
index
IL-2
Reduction
in 1311
Granuloma
post-IL-25
Wg
1 10 48 h <5 20 LL LL subp11 6 + <6 + t -
2 10 48 h 701 30 LL BL 6 + 4-5+ 2-1 + -
3 10 72 h 301 40 LL LL subp11 6 + <6+ t -
4 10 72 h 10 30 LL BL 5 + 3-5+ 2-0+ -
5 25 72 h <5 25 BL BL 4 + 3 + 1 + -
6 25 72 h <5 10 BL BL 3 + 5 + Negative -
7 25 72 h <5 40 BL BL 5 + 4 + 1 + -
8 2 x 10 96 h <5 45 BL LL 5 + 3 + 2 + -
9 3 x 10 7 d 50** 80 LL LL 6+ <6+ t -
10 3 x 10 7 d 40 70 LL BL 6 + 5 + 1 + -
11 3 x 10 12d 80** 70 BL BL 3+ 1+ 2+ +
12 3x10 13d 5 15 BL BT 3+ 1+ 2+ +
13 3 x 10 13 d 15 25 BL BT 4 + 1 + 3 + +
14 3 x 10 19d 40** 80 LL LL 5+ 5+ 0 +
15 3 x 10 19 d 30** 50 LL BL 6+ 5+ 1 + +
16 3 x 10 20 d 70** 95 LL LL 6+ <6+ t +
17 3 x 10 21 d 50** 25 LL BL 6+ 4+ 2+ +
18 3 x 10 21 d 10 20 BL BL 2 + 1 + 1 + -
19 3 x 10 21 d 80** 70 BL BL 4+ 4+ 0 +
20 3 x 10 21 d 40** 70 LL LL 5+ 4+ 1+ +
21 3 x 10 21 d 95** 90 LL BL 6+ 4+ 2+ -
22 3 x 10 21 d 70** 70 LL LL 6 + <6 + t +898
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FIGURE 3 .
￿
T cell accumulation and
subset distribution during a IL-2 re-
sponse . Histologic (Hematoxylin and
eosin) (a)andimmunohistologic stain-
ing of sections with mAbs that recog-
nize all T cells (CD5) (Leu-1) (b and
c) and the CD8' subset of T cells
(Leu-2a) (d). Biopsies were taken 96 h
after IL-2 injections (2 x 10 wg) . At
this early time the majority ofT cells
are of the CD4' subset (x 100 [a] ; x
50 [b] ; and x 200 [c and d]) .
phocytes through the lesion . It is possible that new cells did not continue to enter
the local site in the absence ofadditional lymphokine administration . Instead, many
of the cells either left the dermis and/or were killed and cleared locally within a day
or two. This observation was corroborated by histological sections of the sites biop-sied 48-96 h after IL-2 injection, which revealed extensive cell damage and many
pyknotic nuclei. The lesionsdid not appear necrotic but showed selective death and
clearance of some cells intermixed with intact, viable cells (see below).
T Cells and Their Subsets.
￿
The new inflammatory cells recruited by IL-2 could
be identified as T lymphocytes and monocytes by their surface phenotype (Fig. 3).
At 48 h, the earliest time point examined in detail, the ratio of CD4+ to CD8+ T
cells was over three times that observed in the control lepromatous skin and lesions
(2 :1 vs . 0.6 :1) (Fig. 4B). In the absence ofadditional IL-2 administration, this ratio
returned to control levels by thenext day(Fig. 4B, open triangle). Repeated injections
of rIL-2 maintained both a high number as well as a high ratio of CD4+/CD8 +
cells. By 2 wk the ratio had returned to control levels in all patients while total cel-
lularity was still above that found in the matched control sites. This could be the
result of retention of mononuclear phagocytes and T cells and/or limited continued
emigration.
Effect of IL-2 Administration on the Epidermis.
￿
Microscopic examination of the
epidermis overlying the IL-2 sites revealed extensive epidermal thickening as com-
pared with the matched control sites in all patients biopsied 2-4 d after IL-2 injec-
tion (Fig. 2). The kinetics of thickening corresponded with theaccumulation ofcells
in the dermis (Fig. 4 C). By 7 d a reduction in the thickness of the IL-2-injected
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FIGURE 4.
￿
Kinetics of the localresponse to intradermal administration ofrIL-2. (A) Enhance-
ment of thepercent of the dermis infiltrated by mononuclear cells in response to IL-2. Results
are expressed as the ratio of the percent of area of the dermis infiltrated in the IL-2 injected
site vs. the control site for each patient. (B) T cell subsets expressed as CD4*/CD8' ratio in
therIL-2 injected and control sites. (C)Epidermal thickening in response to IL-2 wasexpressed
as ratio of thickness in the IL-2 injected vs. the control site ofeach patient. The results forfour
individuals (opensymbols) evaluated at 21 d deviated from the majority and are shown separately
as the value in parenthesis. (D) Expression of MHC class II (Ia) and IFN-.y-induced peptide
(IP-10) on keratinocytes. Results expressed as the percent of individuals with positive staining
ofthekeratinocytes in the epidermis after IL-2 injection. All results were evaluated 1-21 d after
thefirstrIL-2injection. Theresults aremeans(A-C) t 1SD (A andB). The numbersin parenthesis
(C) are the number of individuals tested. The open symbols (B and D) denote the results 48 h
after a single injection of 10 ug rIL-2.900
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FIGURE 5 .
￿
la and IP-10 expression
on Keratinocytes andLangerhans'
cell distribution after IL-2 . Im-
munohistologic staining ofsections
with mAbs to MHC class II (9.3)
(a), IFN-,y-induced IP-10 (b), and
CDl' Langerhans' cells (OKT6)
(c) . Biopsies were taken 96 h after
two doses of 10 gg IL-2 (a), 48 h
after 10 lug IL-2 (b), and 21 d after
3 x 10 jug IL-2 (c) . Biopsies taken
from uninjected control sites did
not stain for la or IP-10 (not shown)
(x 200) .
site was observed . 3 wk after IL-2 administration the epidermis overlying the test
site was almost normal in thickness in 9 of 13 patients tested at this time point .
Associated with the thickening of the epidermis were changes in the phenotype
of the keratinocytes overlying these lesions . MHC class II antigen (Ia) andthe IFN-
,y-induced peptide IP-10 were expressed on keratinocytes after IL-2 (Figs . 4D and
5, a and b) . Keratinocytes of control biopsies did not express these antigens (not
shown) . Only 30-40% of individuals tested still expressed laand IP-10 on theirker-KAPLAN ET AL.
FIGURE 6 .
￿
EM micrographs of the selective destruction of parasitized foam macrophages . (a)
IL-2-injected site (3 x 10 kg) biopsied 7 d after lymphokine administration . The parasitized mac-
rophages are disintegrating or damaged (arrows) (x 5,000) . (b)Dead anddamaged macrophages
(arrowheads) in association with viable multinucleated phagocytes (arrow) andmany lymphocytes
(L) (x 3,000) .
901902
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FIGURE 7 .
￿
LocalM . leprae clearance in response to IL-2 injection . (a) Large numbers of bacilli,
many of them intact, in the vacuoles ofthree macrophages (arrows) from a control lesion . (b) Re-
ducednumbers ofM . leprae are seen in the vacuoles ofmacrophages 21 d after the administration
of 3 10-wg doses of rIL-2 into a matched lesion (same patient as a) (x 3,000) .KAPLAN ET AL.
￿
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atinocytes at the site of IL-2 injection by 3 wk. Since la and IP-10 are both IFN-,y-re-
sponsiveness genes, these results are in keeping with the local release of IFN-,y.
Effect ofIL-2 Administration on the Distribution of T6+ Langerhans'Cells.
￿
In control
lepromatous leprosy lesions, T6' Langerhans' cells were evenly distributed in the
epidermis and absent from the dermis (23). AfterIL-2 administration T6+ LC were
prominent in the dermis by 72 h and persisted for as long as 3 wk (Fig. 5 c). No
modification in Langerhans' cell number or distribution was noted in the overlying
epidermis as reported after PPD administration (23).
Mononuclear Phagocyte Differentiation and the Selective Destruction ofParasitizedMacro-
phages. After the IL-2-induced entry of new monocytes into the dermis, the cells
differentiated into epithelioid and multinucleated giant cells (Fig. 6 b). Epithelioid
cell granulomas were observed 12 d aftermultiple injections oflymphokine andper-
sisted for at least 3 wk (Table I). The differentiated mononuclear phagocytes of the
granulomata were observed in association with lymphoid T cells of both the CD4+
and CD8+ phenotype.
Transmission EM revealed extensivelocal destruction ofparasitized macrophages
and foam cells in association with the accumulation of lymphoid cells in the IL-
2-injected sites (Fig. 6 a). Cellular dissolution and extracellulardischarge of cell or-
ganelles, phagolysomes containingM. leprae, and free bacteria wasprominent as early
as 48 h after IL-2 injection.
LocalM. leprae Clearance.
￿
Associated with thedestruction of parasitized andfoamy
macrophages, there was a reduction in the number of M. leprae of the lesion (Fig.
7 and Table I). A patchy reduction of up to 10-fold in M. leprae numbers was ob-
served in sixof sevenpatients biopsied as earlyas 48-72 h afterIL-2 injection (Table
I). In patients biopsied 4-21 d after IL-2 injection, a reduction of 10-1,000-fold in
bacterial numbers was observed in 13 of 15 patients tested. This occurred both in
nodular lesions as well as macular and diffuse lesions of "normal skin," and was as-
sociated with up-grading of the RidleyJopling diagnostic index.
Discussion
We have evaluated the cellular and microbial responses in the skin of LL/BL pa-
tients injected intradermallywith 10-30wgdoses of rIL-2. In doingso, we have recapit-
ulated the essential features of a cell-mediated immune response, previously estab-
lished foran antigen-driven reaction to PPD(9, 10, 22-24). These includeextensive
and persistent emigration of T cells and monocytes, the preponderance of T cells
with a high CD4' /CD8+ ratio, the dermal accumulation of T6 + Langerhans' cells,
the differentiation of mononuclear phagocytes to form granulomata, induction of
expression of keratinocyte Ia and IP-10, and epidermal thickening.
In association with these events there is a striking, selective destruction ofparasit-
ized macrophages. We feel this destruction is an essentialelement in the subsequent
disposal ofM. leprae. We consider theresident infected dermal macrophage defective
in thoseagents that can effectively kill anddigestM. leprae within the phagolysosome
(25, 26). To expose these organisms to aless favorableintracellular milieu, one mech-
anismwould involve theextracellularliberation ofthe bacteria and their subsequent
uptake by newly emigrated, oxidatively competent monocytes (25-28). Priorin vitro
studies indicate that blood-borne monocytes are responsive to the IFN-y produced
(29) by CD4+ and CD8* T cells, NK, and LAK cells. All these cell types are likely904
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candidates for local production of the lymphokine in the dermal site. Thus, working
in concert, macrophage-activating lymphokines and newly emigrated monocytes are
effective in the killing and degradation of viable M. leprae.
Our evidence for killing and degradation ofM. leprae comes largely from quan-
titative morphological studies conducted at the light and electron microscopic level.
The significant and consistent decline in local microbial load is quite remarkable
when one considers the natural history of the disease. Even after microbicidal che-
motherapy, the decline in nonviable organisms in the skin occurs at a rate of only
1 .0 BI units per year (30). In contrast, IL-2 and the cellular response it evokes leads
to the local disposal of 2-3 BI units in 3 wk or an increased removal of bacilli that
exceeds the baseline rate by a factor of 20-200. The response to IL-2 is more rapid
and extensive than that observed either with PPD or rIFN-y (9, 10). Reductions
in organisms occur within 1 wk of IL-2 injection and are as evident in the nodular
lesions ofLL/BL patients and in so-called "normal" skin. rIFN-y modifies the bacil-
lary load of nodular leprosy at a much slower rate (Kaplan et al., manuscript in
preparation).
The requirement for the selective destruction of parasitized macrophages is of con-
siderable interest and may well apply to other situations in which bacteria or pro-
tozoal parasites lead to chronic infection. We have evidence that this occurs with
the infected Kupffer cells of hepatic granuloma in murine Leishmanial infections
(31) and in the local destruction ofLeishmania aethiopica-infected macrophages in chronic
disseminated leishmaniasis in man after IL-2 administration (manuscript in prepa-
ration). Observations made previously by us indicate that a similar scenario takes
place in the natural lesions of paucibacillary tuberculoid leprosy and after the in-
tradermal injection of PPD in presensitized lepromatous patients. In each of these
instances, T cells have been observed in close contact with dead and dying epithelioid
and foamy macrophages containing bacilli and bacillary products . Additional in-
sights are now coming from the in vitro experiments of Hancock et al. (32), which
demonstrate the ability of CD4+ T cells to kill antigen (PPD)-pulsed macrophages
in an antigen-dependent, MHC class II antigen-restricted way. Since many leproma-
tous patients fail to respond to specific M. leprae antigens, we suspect that crossreac-
tive epitopes play a major role in the recognition of the parasitized macrophages
in this form of toxicity. In addition, both NK cells and lymphokine-activated killer
cells can play a less-specific role in macrophage destruction. Our in vitro studies
suggest that PPD stimulation as well as exposure to rIL-2 generate an antigen-inde-
pendent cytotoxic effector population that can kill monocytes in vitro.
The dermal induration and cell infiltration in response to IL-2 is briefer but more
uniform than observed with antigens such as PPD. All patients respond to the lym-
phokine and the unresponsiveness to M. leprae does not appear to affect the respon-
siveness of IL-2 . The doses used in this study are miniscule when compared with
the experience with antitumor therapy (33) but evoke both a local and systemic T
cell response without untoward symptomatology. They are high relative to the amounts
of IL-2 required for cellular activation in vitro (11, 12). In studies to be reported
elsewhere, PBMC from these patients showed more extensive proliferation (TdR
incorporation) to antigens to which they have been previously sensitized after IL-2
injection. Obviously, many other questions remain concerning the effects of IL-2
when injected into the skin. Is it the primary or secondary chemoattractant thatleads to extensive mononuclear cell emigration? What is the nature, source, and
amount of induced molecules synthesized by activated cells in response to IL-2 ad-
ministration? These questions are currently under investigation.
Finally, the use of IL-2 as a therapeutic agent requires additional information
concerning its potential use for parenteral therapy. Studies in mice have shown that
IL-2 administered subcutaneously can protect the animals against infections and
enhance their immunity (34-36). We do not know whether, ifused parenterally, IL-
2 could enter and modify the dermis of LL/BL patients or whether local modifica-
tions ofendothelial permeability would be required. Parenteral IL-2 has been shown
to activate the endothelium, enhance vascular permiability, and induce dermatolog-
ical changes, including migration of T cells into the skin (37, 38). These are ques-
tions for the future but ones that are pertinent for a wide range ofintracellular parasites.
Summary
Human rIL-2 (10-30 ug) was injected intradermally into the skin of patients with
lepromatous leprosy with high bacillary loads. All patients responded to the lym-
phokine with local areas of induration that peaked at 24 h and persisted for 4-7 d
irrespective of whether the site was "normal skin" or a nodular lesion. Within 24 h
there was an extensive emigration of T cells and monocytes into the site. The per-
centage ofthe dermis infiltrated by mononuclear cellsincreased by more than seven-
fold, peaking at 4 d and persisting for >15 d. Both CD4+ and CD8+ T cells en-
tered the site. T cells of CD4+ phenotype predominated at 2-7 d but by 11 d, CD8+
cells were predominant. Considerable numbers of T6+ Langerhans' cells appeared
in the dermis by 72 h and persisted for 3 wk. By 4 d the thickness of the overlying
epidermis had increased twofold, and keratinocytes were expressing MHC class II
antigen and the IFN-y-induced peptide IP-10.
Starting at 48 h, there was an extensive destruction of mononuclear phagocytes
that contained structurally intact or fragmented M. leprae observed at the electron
microscope level. The organisms, either free or contained within endocytic vocuoles,
were discharged into the extracellular spaceand then reingested by blood-borne mono-
cytes. This was followed by marked reductions in the number ofacid-fast organisms
in the injected site, evident as early as 4-7 d and more marked at 2-3 wk after injec-
tion . 13 of 15 patients exhibited a disposal of acid-fast bacilli ranging from 5- to
1,000-fold with a mean value of -100-fold .
The administration of IL-2 leads to the generation of an effective cell-mediated
immune response, recapitulating an antigen-driven event and leading to striking
local reductions in M. leprae. In comparison with the purified protein derivative of
tuberculin reaction, bacilli are cleared more promptly, although emigratory cells
persist for a shorter time.
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